Company / Capital Expenditures
ALX ONCOLOGY HOLDINGS INC Capital Expenditures History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.4M
FY2022
5-year range
$353.0K / $1.4M
FY2020-FY2022
Trend
+304.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +304% YoY in FY2022, a notable deviation from the 2-year average annual change of +129%.
Based on SEC 10-K filings.
$1M in FY2022.
Improved from $653,000 to $1M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, capital expenditures increased 304.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $1.4M | +304.2% |
| FY2021 | $353.0K | -45.9% |
| FY2020 | $653.0K | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026